A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.
Stefan Kasper
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Other Remuneration - Merck Serono
Friedrich Overkamp
No relevant relationships to disclose
Markus Hermann Moehler
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Other Remuneration - Merck Serono
Frank Kullmann
No relevant relationships to disclose
Hauke Lang
No relevant relationships to disclose
Michael Schoen
No relevant relationships to disclose
Victoria Smith-Machnow
No relevant relationships to disclose
Susanna Hegewisch-Becker
No relevant relationships to disclose
Daniel Seehofer
No relevant relationships to disclose
Wolf Bechstein
No relevant relationships to disclose
Michael Heike
No relevant relationships to disclose
Matthias Voehringer
No relevant relationships to disclose
Volker Heinemann
No relevant relationships to disclose
Richard Greil
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Michael Geissler
No relevant relationships to disclose
Florian Lordick
Consultant or Advisory Role - Amgen; Fresenius Biotech; GANYMED Pharmaceuticals; Lilly; Roche
Honoraria - Amgen; Fresenius Biotech; Merck KGaA; Roche
Research Funding - GlaxoSmithKline; Merck; Sanofi
Marc Peeters
No relevant relationships to disclose
Eric Van Cutsem
No relevant relationships to disclose
Peter Robert Galle
No relevant relationships to disclose
Carl Christoph Schimanski
Research Funding - Merck Serono
Other Remuneration - Merck KGaA